Pharmacokinetics and pharmacodymanics study of doctaxel in patients with non-small cell lung cancer
Not Applicable
- Conditions
- Advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000014701
- Lead Sponsor
- Shizuoka cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with interstitial pneumonitis identified by chest X-ray
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie doctaxel's pharmacodynamic effects in advanced NSCLC patients?
How does doctaxel compare to standard-of-care chemotherapies in advanced NSCLC efficacy and toxicity?
Which biomarkers correlate with doctaxel response in Shizuoka Cancer Center's NSCLC PK/PD study?
What adverse events are associated with doctaxel in NSCLC and how are they managed?
Are there combination therapies involving doctaxel and other agents for NSCLC treatment?